Core Alternative Capital Has $5.33 Million Stock Holdings in Medtronic PLC $MDT

Core Alternative Capital increased its position in Medtronic PLC (NYSE:MDT) by 35.8% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 55,911 shares of the medical technology company’s stock after acquiring an additional 14,736 shares during the quarter. Medtronic accounts for 1.5% of Core Alternative Capital’s holdings, making the stock its 20th largest position. Core Alternative Capital’s holdings in Medtronic were worth $5,325,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in MDT. Norges Bank acquired a new position in shares of Medtronic during the second quarter worth $1,432,698,000. Vanguard Group Inc. lifted its holdings in Medtronic by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 126,909,406 shares of the medical technology company’s stock worth $11,062,693,000 after buying an additional 1,895,165 shares during the period. Arrowstreet Capital Limited Partnership grew its position in shares of Medtronic by 332.0% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,494,782 shares of the medical technology company’s stock valued at $130,300,000 after buying an additional 1,148,803 shares during the last quarter. Laurel Wealth Advisors LLC increased its stake in shares of Medtronic by 8,779.8% in the second quarter. Laurel Wealth Advisors LLC now owns 1,069,664 shares of the medical technology company’s stock valued at $93,243,000 after buying an additional 1,057,618 shares during the period. Finally, Altrinsic Global Advisors LLC raised its position in shares of Medtronic by 47.7% during the second quarter. Altrinsic Global Advisors LLC now owns 2,688,334 shares of the medical technology company’s stock worth $234,342,000 after acquiring an additional 868,256 shares during the last quarter. 82.06% of the stock is owned by institutional investors.

Medtronic Stock Up 0.0%

Shares of NYSE:MDT opened at $100.71 on Wednesday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. Medtronic PLC has a 52-week low of $79.55 and a 52-week high of $106.33. The business’s 50 day simple moving average is $99.52 and its two-hundred day simple moving average is $95.48. The firm has a market cap of $129.12 billion, a P/E ratio of 27.15, a PEG ratio of 2.65 and a beta of 0.71.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. The company had revenue of $8.96 billion for the quarter, compared to analysts’ expectations of $8.86 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.Medtronic’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same period last year, the business earned $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, research analysts forecast that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were paid a dividend of $0.71 per share. The ex-dividend date was Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a yield of 2.8%. Medtronic’s payout ratio is 76.55%.

Wall Street Analyst Weigh In

A number of research firms have weighed in on MDT. William Blair raised shares of Medtronic from a “market perform” rating to an “outperform” rating in a research report on Tuesday, January 6th. Piper Sandler reiterated a “neutral” rating on shares of Medtronic in a research report on Monday, January 5th. The Goldman Sachs Group set a $111.00 target price on shares of Medtronic and gave the stock a “neutral” rating in a research note on Wednesday, November 19th. Leerink Partners set a $120.00 price target on shares of Medtronic and gave the company an “outperform” rating in a research report on Wednesday, November 19th. Finally, Wall Street Zen upgraded Medtronic from a “hold” rating to a “buy” rating in a report on Friday, January 23rd. Fourteen analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $110.28.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).